Conference

    Early Detection of Cancer Annual Conference - EDx25

    Held October 21–23, 2025 in Portland, Oregon, EDx25 convened international experts to share advances in AI, multi-cancer early detection, next-generation biomarkers, and bringing early detection into primary care and communities.

    Renata Barnes
    Published:
    6 min read

    The Early Detection of Cancer Conference (EDx25) was held October 21–23, 2025 in Portland, Oregon, USA. Presented by Cancer Research UK, the Canary Center at Stanford, and the OHSU Knight Cancer Institute, the meeting brought together researchers, clinicians, technologists, and public health leaders to translate cutting-edge discovery into real-world early detection.

    Across sessions, speakers highlighted the role of artificial intelligence, innovative technologies, and the practical work of getting early detection into the community and primary care—so clinicians can focus testing and follow-up on the people who need it most.

    Key highlights from EDx25

    Long-term registry follow-up for MCED in symptomatic patients

    One major update featured long-term data from the SYMPLIFY study (GRAIL and the University of Oxford), evaluating the Galleri multi-cancer early detection (MCED) test in symptomatic individuals.

    • With follow-up extended to 24 months in national cancer registries, the positive predictive value (PPV) increased to 84.2% (up from 75.5%).
    • About one-third of participants initially considered “false positive” were later diagnosed with cancer during extended follow-up.
    • These results reinforce the test’s ability to predict the cancer signal origin and the value of longer-term outcome capture when evaluating early detection tools.

    Innovation across AI, biomarkers, and liquid biopsy

    The agenda emphasized how new technologies—and the way we evaluate them—can accelerate early detection while supporting clinical adoption. Talks highlighted:

    • How AI can support detection, triage, and decision-making across screening and diagnostic pathways.
    • Emerging biomarker strategies and assay designs aimed at improving early-stage sensitivity and specificity.
    • Implementation-oriented research focused on pathways that work in real care settings.

    DNA methylation signals that sharpen colorectal cancer detection

    Research presented at EDx25 demonstrated that distinguishing between DNA methylation types 5mC and 5hmC can significantly enhance the diagnostic accuracy of liquid biopsy tests for early-stage colorectal cancer (AUC = 0.95).

    Primary care integration and community impact

    A recurring theme was the importance of moving early detection strategies into community and primary care settings—where most patients first present—so that risk-informed tools and pathways can help identify who should receive further testing.

    Collaboration across disciplines and institutions

    Hosted by Cancer Research UK, the Canary Center at Stanford, and the OHSU Knight Cancer Institute, EDx25 underscored international, multidisciplinary collaboration as essential for progress in early detection—bringing together experts in research, clinical practice, engineering, and public health to accelerate translation and improve outcomes through earlier diagnosis.

    Learn more about the Early Detection of Cancer Conference at earlydetectionresearch.com.

    Tags:
    EDx25
    Conference
    Portland
    Cancer Research UK
    Stanford
    OHSU
    Collaboration
    AI
    MCED
    Galleri
    SYMPLIFY
    Liquid Biopsy
    Biomarkers
    DNA Methylation
    Primary Care
    Colorectal Cancer

    About Renata Barnes

    Renata Barnes is a science communications specialist at the Canary Foundation, dedicated to sharing breakthrough research in early cancer detection.